 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of Olaparib (Olaparib) Monotherapy for Maintenance of Platinum-Sensitive Relapsed Ovarian Cancer in Asian Population: Phase III Clinical Study L-MOCA

Clin Cancer Res: Efficacy of Olaparib (Olaparib) Monotherapy for Maintenance of Platinum-Sensitive Relapsed Ovarian Cancer in Asian Population: Phase III Clinical Study L-MOCA

 Last Update: 2022-03-04
 Source: Internet
 Author: User

Tags

skin cancer images

open source programs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Olaparib (olaparib) single-agent maintenance therapy improves PFS in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) compared with placebo
.

However, its efficacy in Asian populations is unclear

Olaparib (olaparib) single-agent maintenance therapy improves PFS in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) compared with placebo

The study is an open-label, single-arm phase III study in patients with high-grade epithelial PSR OC in China and Malaysia
.

The patient received oral olaparib 300 mg bid until disease progression or intolerable toxicity

The study is an open-label, single-arm phase III study in patients with high-grade epithelial PSR OC in China and Malaysia

From 2018 to 2020, 225 patients were included, of whom 224 received olaparib

More than half (58.

The median follow-up time was 15.

In subgroup analysis, median PFS was 21.
2 months (95% CI 16.
4-24.
9) and 11.
0 months (95% CI 8.
3-15.
8) for BRCAm and BRCAwt patients, respectively
.

Further subgroup analysis of BRCAm patients showed that the mPFS of sBRCAm and gBRCAm patients was 16.

In subgroup analysis, median PFS was 21.

mPFS was 15.
8 months (95% CI 11.
0 18.
2) in patients <65 years and 19.
7 months (95% CI 11.
1-22.
2) in patients ≥65 years
.

Median PFS was 19.

mPFS was 15.

Serious AEs occurred in 57 cases (25.
4%), including 39 cases (17.
4%) related to treatment
.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) occurred in 3 cases (1.
3%), 2 of which occurred during treatment
.

The incidence of AEs of any CTCAE grade was 99.
1 %; the most common AEs of any grade were anemia (76.
4%), nausea (54.
0%), and leukopenia (24.
1%).
48.
7% of patients reported grade 3 or higher AEs; among them, anemia (25.
0%), decreased neutrophil count (14.
3%) and 48.
7% of patients reported; among them, anemia (25.
0%), decreased neutrophil count (14.
3%), decreased platelet count ( 4.
9%) the most common
.
Serious AEs occurred in 57 cases (25.
4%), including 39 cases (17.
4%) related to treatment
.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) occurred in 3 cases (1.
3%), 2 of which occurred during treatment
.
99.
1

In conclusion, the study confirmed that Olaparib (olaparib) single-agent maintenance treatment of platinum-sensitive recurrent ovarian cancer (PSR OC) in Asian population is highly effective and well tolerated
.
The study confirmed that Olaparib (olaparib) single-agent maintenance treatment of platinum-sensitive recurrent ovarian cancer (PSR OC) in Asian population is highly effective and well tolerated
.
The study confirmed that Olaparib (olaparib) single-agent maintenance treatment of platinum-sensitive recurrent ovarian cancer (PSR OC) in Asian population is highly effective and well tolerated
.

Original source:

Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J, Kong B, Rozita AM, Sen LC , Yin R, Xie X, Liu J, Sun W, Su J, Zhang C, Zang R, Ma D.
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
Clin Cancer Res.
2022 Feb 7:clincanres.
3023.
2021.
doi: 10.
1158/1078-0432.
CCR-21-3023.
Epub ahead of print.
PMID: 35131903.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.